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Abstract
Background: The current study sought to define the impact of lymph node metastasis
(LNM) relative to tumor size on tumor recurrence after curative resection for
nonfunctional pancreatic neuroendocrine tumors (NF‐pNETs) ≤2 cm.
Methods: Patients who underwent curative resection for ≤2‐cm NF‐pNETs were
identified from a multi‐institutional database. Risk factors associated with tumor
recurrence as well as LNM were identified. Recurrence‐free survival (RFS) was
compared among patients with or without LNM.
Results: A total of 392 ≤2‐cm NF‐pNETs patients were identified. Among the 328
patients who had lymph node dissection and evaluation, 42 (12.8%) patients had
LNM. LNM was associated with tumor recurrence (hazard ratio, 3.06; P = .026) after
surgery. RFS was worse among LNM vs no LNM patients (5‐year RFS, 81.7% vs
94.1%; P = .019). Patients with tumors measuring 1.5‐2 cm had a two‐fold increase in
the incidence of LNM vs patients with tumors <1.5 cm (17.9% vs 8.7%, odds ratio,
2.59; P = .022), as well as a higher risk of advanced tumor grade and higher Ki‐67
levels (both P < .01). After curative resection, a total of 14 (8.0%) patients with a
tumor of 1.5‐2 cm and 10 (4.5%) patients with tumor <1.5 cm developed tumor
recurrence.
Conclusion: Surgical resection with lymphadenectomy should be considered for
patients with NF‐pNETs ≥1.5‐2.0 cm.
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1 | INTRODUCTION
Pancreatic neuroendocrine tumors (pNETs) are a collection of rare
neoplasms with a wide variety of biologic aggressiveness. The
incidence of pNETs has increased over the past few decades with
an almost doubling in the identification of these tumors concurrent
with improvements in cross‐sectional imaging.1-3 Based on symptoms
and hormone secretion, pNETs are generally classified as functional
(F‐pNETs) vs nonfunctional pNETs (NF‐pNETs) with the majority of
tumors (65%‐90%) being classified in the latter group.4,5 The lack of
early symptoms among patients with NF‐pNETs often leads to late
discovery, more advanced stage at diagnosis, and worse long‐term
outcomes compared with patients who have F‐pNETs.6-8
According to the European Neuroendocrine Tumor Society
(ENETS) and American Joint Committee on Cancer (AJCC) 8th
Edition Staging Manual Guidelines, surgical resection is recom-
mended for NF‐pNETs >2 cm.9,10 The management of patients with
NF‐pNETs ≤2 cm is, however, more controversial. Due to the
relatively low tendency to progress as well as the potential morbidity
associated with pancreatic resection, some investigators have
advocated for observation and surveillance of NF‐pNETs ≤2 cm as
the preferred management strategy.11-13 Other experts, however,
have highlighted the potential for malignant differentiation, lymph
node metastasis (LNM), and distant metastasis even among patients
with small NF‐pNETs and therefore have argued for resection.14-16
The topic is particularly important given that the incidence of NF‐
pNETs ≤2 cm in the United States has increased dramatically over
the past two decades with the proportion of patients with NF‐pNETs
≤2 cm increasing from 12.3% in 1988 to 20.2% in 2009.17
Currently, both the ENETS and the National Comprehensive
Cancer Network recommend an individualized treatment strategy for
small NF‐pNETs that may involve resection or observation as
dictated by clinical judgment, as well as patient risk and prefer-
ence.9,18 As such, the optimal treatment strategy of small NF‐pNETs
remains uncertain, and the guidelines are often unclear and not
applicable to a “real life” setting.19 In addition, as minimally invasive
techniques have expanded, more and more surgeons have adopted
surgical resection for pNETs regardless of lesion size.17,20,21 Most
previous data have focused on tumor size and LNM as risk factors
associated with long‐term outcomes following resection of
pNETs.4,5,21,22 In contrast, the incidence of LNM relative to tumor
size on prognosis among patients with NF‐pNETs ≤2 cm has not been
well defined. Therefore, the objective of the current study was to
define the impact of tumor size on risk of LNM, as well as to
characterize the association of tumor size and LNM among patients
undergoing curative‐intent resection for small NF‐pNETs ≤2 cm.
2 | MATERIALS AND METHODS
2.1 | Study cohort
Patients who underwent surgical resection for pNETs between 1997
and 2016 were identified from the US Neuroendocrine Tumor Study
Group.23 Inclusion criteria for the current study were patients with
(a) nonfunctional tumor, (b) largest tumor diameter ≤2 cm, and (c)
curative‐intent resection (R0/R1). Exclusion criteria included (a)
presence of distant metastasis, (b) death within 90 days after
operation, and (c) cytoreductive or palliative (R2) resection. NF‐
pNETs were defined as asymptomatic if the tumor had no evidence of
hormone overproduction; patients with no tumor‐related hormone
function who had symptoms related to tumor expansion and
invasiveness, such as abdominal pain, jaundice, weight loss, etc were
still categorized as NF‐pNETs.10 The study was approved by the
Institutional Review Boards at each participating institution.
2.2 | Data collection
Demographic, clinical, and pathologic data at each institution were
collected using a standardized datasheet. Tumor size, primary tumor
location, the total number of LNs examined (TNLE), the number of
LNM, Ki‐67, tumor differentiation, perineural invasion, vascular
invasion, and surgical margin status were determined based on the
final pathological report. A minimum margin width of >1mm was
designated as an R0 margin; an R1 margin was defined as the
microscopic presence of tumor at the margin or a minimum margin
length of ≤1mm.24
Following surgery, each patient was followed regularly with
ultrasonography, computed tomography, and/or magnetic resonance
imaging to monitor for recurrence. Recurrence of NF‐pNETs was
determined by suspicious imaging finding or biopsy‐proven tumor.
Recurrence patterns were classified as pancreas‐only and distant
recurrence. Recurrence‐free survival (RFS) was defined as the time
from surgical resection to tumor recurrence.
2.3 | Statistical analysis
Categorical variables were reported as totals and percentages. The χ2
test or the Fisher exact test was used for comparison, as
appropriated. Continuous variables were expressed as median with
interquartile ranges (IQRs) and compared using the Mann‐Whitney U
test. Kaplan‐Meier survival curves were plotted and compared using
the log‐rank test. Cox‐proportional hazard regression models were
used to identify risk factors associated with RFS on univariate and
multivariable analyses; results were reported as hazard ratios (HRs)
and 95% confidence intervals (95% CI). Logistic regression models
were used to identify factors associated with LNM with results as
odds ratio (OR) and 95% CI. A P value < .05 (two‐tailed) was
considered statistically significant for all analyses. Statistical analyses
were performed using SPSS 22.0 (IBM, Chicago, IL).
3 | RESULTS
3.1 | Baseline characteristics
Among 989 patients who underwent curative‐intent resection for
NF‐pNETs, a total of 392 (39.6%) patients had a primary tumor
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≤2 cm and comprised the analytic cohort (Table 1). The median
age was 59 (IQR 50‐66) years, and roughly half of the cohort was
female (n = 204, 52.0%). A majority of patients had no genetic
syndrome (n = 349, 89.3%), and more than one‐half of patients
were diagnosed incidentally without any antecedent symptoms
(n = 213, 54.3%). Given that most NF‐pNETs were located in the
pancreatic tail (n = 175, 44.6%), the most common procedure was
a distal pancreatectomy (n = 237, 60.5%). Median operative time
was 235 (IQR 190‐315) minutes with a median estimated blood
loss of 200 (IQR 50‐300) mL. In the postoperative period, 227
(58.1%) patients had at least one complication; roughly one‐third
of these patients (n = 87, 38.5%) experienced a Clavien‐Dindo III‐
IV complication. On final pathology, most tumors were well‐
differentiated (n = 325, 92.6%) and had a low ki‐67 < 3% (n = 207,
73.4%). R0 resection was achieved in the overwhelming majority
of patients (n = 354, 90.5%).
3.2 | Lymph node metastasis and tumor recurrence
After a median follow‐up of 33.7 (IQR 12.0‐59.4) months, only 24
(6.1%) patients experienced tumor recurrence. The 3‐, 5‐, and 10‐
year RFS for the entire cohort was 95.1%, 91.9%, and 75.1%,
respectively. On univariate analysis, only LNM was associated
with tumor recurrence (HR 3.06, 95% CI, 1.15‐8.17; P = .026)
(Table 2). Among the 328 patients who had a lymph node
dissection, the incidence of LNM was 12.8% (n = 42) with the vast
majority of patients having node‐negative disease (n = 286,
87.2%). Perhaps not surprisingly, patients with LNM were more
likely to have an associated genetic syndrome, high Ki‐67, as well
as perineural invasion compared with patients who had node‐
negative disease (Table 1). RFS among patients with LNM was
worse compared with patients who had node‐negative disease
(5‐year RFS, LNM 81.7% vs node‐negative 94.1%; P = .019)
(Figure 1).
3.3 | Tumor size and nodal metastasis
On multivariable analysis, tumor size (1.5‐2.0 cm vs <1.5 cm, OR,
2.59, 95% CI, 1.15‐5.83; P = .022) and Ki‐67 category (≥3% vs <3%,
OR, 2.20, 95% CI, 1.02‐4.78; P = .045) were independently associated
with risk of LNM (Table 3). Specifically, the incidence of LNM was
almost two‐fold higher among patients with 1.5‐2 cm NF‐pNETs
(n = 145) vs <1.5 cm NF‐pNETs (n = 183) (LNM, 1.5‐2 cm 17.9% vs
TABLE 1 Clinical and pathological characteristics of the study
cohort with NF‐pNETs ≤2.0 cm
Variables
Overall LNM No LNM
P(n = 392) (n = 42) (n = 286)
Age, y 59 (50‐66) 55 (46‐65) 60 (50‐66) .288
Sex .841
Female 204 (52.0%) 20 (47.6%) 150 (52.4%)
Male 188 (48.0%) 22 (52.4%) 136 (47.6%)
Genetic syndrome .004
None 349 (89.3%) 29 (69.0%) 259 (90.9%)
MEN‐1 37 (9.5%) 12 (28.6%) 23 (8.1%)
VHL 4 (1.0%) 1 (2.4%) 3 (1.1%)
Symptomatic .079
No 213 (54.3%) 16 (38.1%) 162 (56.6%)
Yes 179 (45.7%) 26 (61.9%) 124 (43.4%)
Primary location .000
Head 95 (24.2%) 26 (61.9%) 61 (21.3%)
Uncinated 15 (3.8%) 1 (2.4%) 10 (3.5%)
Neck 28 (7.1%) 3 (7.1%) 21 (7.3%)
Body 79 (20.2%) 1 (2.4%) 60 (21.0%)
Tail 175 (44.6%) 11 (26.2%) 134 (46.9%)
Ki‐67 category .022
<3% 207 (73.4%) 17 (51.5%) 155 (74.2%)




Well 325 (92.6%) 34 (89.5%) 236 (92.2%)
Moderately 26 (7.4%) 4 (10.5%) 20 (7.8%)
Surgical technique .006
Open 278 (70.9%) 39 (92.9%) 197 (68.9%)
Laparoscopic/
robotic
114 (29.1%) 3 (7.1%) 89 (31.1%)
Type of resection .000
Enucleation 39 (9.9%) 4 (9.5%) 11 (3.8%)
Classic PD 36 (9.2%) 10 (23.8%) 25 (8.7%)
Pylorus
preserving PD
52 (13.3%) 14 (33.3%) 38 (13.3%)
Central
pancreatectomy
24 (6.1%) 1 (2.4%) 11 (3.8%)
Distal
pancreatectomy
237 (60.5%) 12 (28.6%) 198 (69.2%)
Total
pancreatectomy
4 (1.0%) 1 (2.4%) 3 (1.0%)
Perineural invasion 40 (13.3%) 12 (37.5%) 26 (11.9%) .000
Major vascular
resection
5(1.3%) 2(4.9%) 2(0.7%) .083















R0 354 (90.5%) 32 (78.0%) 266
(93.0%)
R1 37 (9.5%) 9 (22.0%) 20 (7.0%)
Postoperative
morbidity




Overall LNM No LNM
P(n = 392) (n = 42) (n = 286)
Severe complication
(III‐IV)
87 (38.5%) 12 (50.0%) 61 (37.9%) .515
Abbreviations: LNM, lymph node metastasis; PD, pancreatoduodenectomy.
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TABLE 2 Risk factors of tumor recurrence after curative resection
for NF‐pNETs ≤2 cm
Univariate analysis
Variable HR (95% CI) P
Gender (F/M) 0.75 (0.33‐1.71) .487
Age (<65/≥65) 0.40 (0.12‐1.35) .140










Tumor size, cm .137
<1.5 Ref.
1.5‐2 1.85 (0.82‐4.18)
Lymph nodes metastasis 3.06 (1.15‐8.17) .026
Perineural invasion 1.19 (0.34‐4.17) .783




Abbreviation: CI, confidence interval; HR, hazard ratio.
F IGURE 1 Recurrence‐free survival of patients with or without lymph nodal metastasis (LNM) in the whole cohort (n = 392)










































Abbreviations: CI, confidence interval; OR, odds ratio.
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<1.5 cm 8.7%) (OR, 2.28, 95% CI, 1.17‐4.44; P = .015) (Figure 2A),
although TNLE and number of LNM were no different among
patients with 1.5‐2 cm NF‐pNETs vs <1.5 cm NF‐pNETs (TNLE,
median 9 vs 8; P = .734; number of LNM, median 2 vs 1.5; P = .287)
(Figure 2B,C).
In addition to a higher incidence of LNM, 1.5‐2 cm NF‐pNETs
were associated with more advanced disease including a Ki‐67 ≥3%
(1.5‐2 cm 35.9% vs <1.5 cm 18.8%; P = .001), as well as worse WHO
tumor grade (G2 grade, 1.5‐2 cm 29.2% vs <1.5 cm 13.9%; P = .001)
vs patients with a NF‐pNETs <1.5 cm (Table 4). Of note, after
curative resection, a total of 14 (8.0%) patients with tumors 1.5‐2 cm
and 10 (4.5%) patients with a tumor <1.5 cm developed tumor
recurrence. RFS was no different among patients with NF‐pNETs that
measured 1.5‐2 cm vs NF‐pNETs <1.5 cm (5‐year RFS, 1.5‐2 cm
87.3% vs <1.5 cm 95.6%; P = .131) (Figure 3A). In addition, recurrence
patterns were no different among patients with NF‐pNETs of 1.5‐
2 cm and NF‐pNETs <1.5 cm (distant recurrence, 64.3% vs 50.0%;
P = .484) (Figure 3B).
4 | DISCUSSION
The treatment strategy for small NF‐pNETs (≤2 cm) remains
controversial, as both surgical resection and observation are
recommended according to various guidelines.10,16 One of the
main challenges in the management of small NF‐pNETs is an
accurate assessment of the natural history of the disease, as well
as the ability to predict the risk of LNM and long‐term outcomes.
F IGURE 2 A, Incidence of lymph node metastasis (LNM) among patients with tumor <1.5 cm vs patients with a tumor of 1.5‐2 cm. The total
number of lymph nodes examined (B) and the number of LNM (C) of each patient in the two differently sized tumor groups
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The clinical course of NF‐pNETs ≤2 cm has not been well defined
and, therefore, many surgeons often advocate for surveillance of
these small tumors.17,20,21 Given that the general incidence of
NF‐pNETs is relatively low and most previous studies have been
single‐center series with small sample sizes, data on NF‐pNETs
<2 cm remain scarce. The current study was important because it
demonstrated that roughly 40% of patients who underwent
curative resection for NF‐pNETs at one of several large HPB
centers had a tumor size ≤2 cm. Of note, patients with a small NF‐
pNET had a two‐fold increased incidence of LNM if the tumor
measured 1.5‐2 cm vs <1.5 cm (17.9% vs 8.7%; P = .015). Further-
more, LNM were present among 12.8% of patients with an NF‐
pNET ≤2 cm. In turn, LNM was associated with a three‐fold
increased risk of tumor recurrence after curative resection and a
worse RFS vs patients who had no nodal disease after surgery (5‐
year RFS, nodal positive 81.7% vs nodal negative 94.1%; P = .019).
Collectively, the data strongly suggest that surgery for NF‐pNETs
should be performed among patients with a tumor size ≥1.5 cm
because of the relatively high incidence of LNM.
Some investigators have proposed that surveillance of NF‐pNETs
≤2 cm is safe, as most of these tumors grow very slowly with no
disease‐related death among patients undergoing active surveil-
lance.12,13 Data from two meta‐analyses demonstrated that pNET
tumor growth was observed in 50% of patients with small NF‐pNET
≤2 cm; in addition, 9% of patients developed metastasis during
surveillance.12,13 In a separate study of patients with NF‐pNETs
≤2 cm derived from the National Cancer Data Base (NCDB), the
authors reported a 5‐year overall nondisease‐specific survival of
27.6% among patients who did not undergo surgery compared with a
5‐year survival of 82.2% among patients who underwent curative‐
intent resection.15 In the current study that examined surgical
patients exclusively, RFS of 3‐ and 5‐year RFS were 95.1% and 91.9%,
respectively. Data from the current data were, therefore, more
optimistic about the disease‐specific prognosis for patients with small
NF‐pNETs ≤2 cm. Specifically, compared with the 5‐year mortality of
18% reported in the NCDB study, we noted 5‐year recurrence to be
only about 8% of patients following resection of small pNETs. Our
data were more consistent with the expected good prognosis of this
patient population and likely reflected that the previous NCDB study
captured all‐cause mortality events, which included deaths not
related to pNETs. In the current study, 5‐year RFS among patients
with NF‐pNETs <1.5 (95.6%) tended to be better than the prognosis
of patients with NF‐pNETs measuring 1.5‐2 cm (87.3%). In an earlier
study by Zhang et al,25 the authors reported that surgical resection
had the most long‐term benefit among patients with pNETs ≥1.5 cm,
while resection failed to demonstrate a difference in survival
compared with surveillance among individuals with tumors <1.5 cm.
Taken together, patients with NF‐pNETs measuring 1.5‐2 cm should
be strongly considered for surgical resection, whereas patients with
tumor <1.5 cm may be more appropriate candidates for surveillance.
TABLE 4 Clinical and pathological characteristics of patients with





(n = 171) P
Age, y 59 (50‐66) 59 (50‐67) .119
Sex .416
Female 119 (53.8%) 85 (49.7.%)
Male 102 (46.2%) 86 (50.3%)
Genetic syndrome .323
None 201 (91.0%) 148 (87.1%)
MEN‐1 19 (8.6%) 18 (10.6%)
VHL 1 (0.5%) 3 (1.8%)
Symptomatic .098
No 112 (50.7%) 101 (59.1%)
Yes 109 (49.3%) 70 (40.9%)
Primary location .072
Head 54 (24.4%) 41 (24.0%)
Uncinated 9 (4.1%) 6 (3.5%)
Neck 13 (5.9%) 15 (8.8%)
Body 55 (24.9%) 24 (14.0%)
Tail 90 (40.7%) 85 (49.7%)
Ki‐67 category .001
<3% 125 (81.2%) 82 (64.1%)
>3% 29 (18.8%) 46 (35.9%)
Tumor differentiation .064
Well 186 (94.9%) 139 (89.7%)
Moderately 10 (5.1%) 16 (10.3%)
WHO grade .001
G1 149 (86.1%) 97 (70.8%)
G2 24 (13.9%) 40 (29.2%)
Lymph nodes metastasis 16 (8.7%) 26 (17.9%) .013
Surgical technique .064
Open 165 (74.7%) 113 (66.1%)
Laparoscopic/robotic 56 (25.3%) 58 (33.9%)
Type of resection .571
Enucleation 21 (9.5%) 18 (10.5%)
Classic PD 16 (7.2%) 20 (11.7%)
Pylorus preserving PD 32 (14.5%) 20 (11.7%)
Central pancreatectomy 16 (7.2%) 8 (4.7%)
Distal pancreatectomy 134 (60.6%) 103 (60.2%)
Total pancreatectomy 2 (0.9%) 2 (1.2%)
Perineural invasion 24 (14.0%) 16 (12.4%) .681
Major vascular resection 3 (1.4%) 2 (1.2%) .877
Lymphadenectomy 183 (82.8%) 145 (84.8%) .584
Operation time, min 235 (184‐311) 220 (189‐304) .253
Blood loss, mL 200 (100‐350) 200 (100‐300) .004
Margin status .505
R0 202 (91.4%) 152 (89.4%)
R1 19 (8.6%) 18 (10.6%)
Postoperative morbidity 126 (57.3%) 101 (59.1%) .722
Severe complication (III‐V) 53 (41.7%) 34 (34.3%) .257
Abbreviation: PD, pancreatoduodenectomy.
1076 | DONG ET AL.
F IGURE 3 A, Recurrence‐free survival of patients with different tumor size (<1.5 cm, n = 221 vs 1.5‐2 cm, n = 171). B, Recurrence patterns
among patients with tumor <1.5 cm vs patients with tumor of 1.5‐2 cm after curative resection
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While patients with small NF‐pNET generally had a good
prognosis, several factors were associated with a worse long‐term
survival, including tumor size, grade, and LNM. In particular, tumor
size (1.5‐2 cm vs <1.5 cm) was linked with a higher Ki‐67 level, as well
as more advanced WHO grade (Table 3). Jung et al26 had similarly
reported that patients with a tumor measuring 1.5‐2 cm had a higher
likelihood to be WHO G2/G3 tumors vs tumors <1.5 cm. Tumor size,
therefore, correlated with the potential for the presence of other
adverse pathological features. In particular, the risk of recurrence
was nearly two‐fold higher among patients with tumors ≥1.5 cm
(8.2%) compared with patients who had tumors <1.5 cm (4.5%)—
suggesting a subset of patients with NF‐pNETs ≤2 cm had a more
aggressive natural history. Interestingly, among patients who did
recur, the pattern of recurrence was no different comparing patients
with tumor NF‐pNET <1.5 cm vs ≥1.5 cm.
The presence of LNM has been particularly associated with an
increased risk of tumor recurrence (Table 2). The need for routine
performance of lymphadenectomy at the time of resection for
NF‐pNETs ≤2 cm is, however, somewhat controversial.5,15,17,21,27 National
Cancer Center Network guidelines recommend regional lymph node
evaluation at the time of resection for NF‐pNETs, irrespective of tumor
size.9,18 Despite this, some clinicians have suggested that enucleation of
smaller pNETs without nodal evaluation may be acceptable.15,28 Our
group previously reported that regional lymphadenectomy of at least
eight lymph nodes was necessary to stage patients with pNETs
accurately.23 In the current study, the median TNLE were eight and nine
among patients with pNETs <1.5 cm and 1.5‐2.0 cm, respectively (Figure
2B,C), suggesting that roughly half of the patients had an adequate
number of LNs examined. Data on nodal disease is important as the
presence of LNM renders the disease stage III regardless of tumor size
both in the AJCC and ENETS staging systems.10,29-32 In the current study,
LNM was noted in more than 1 in 10 patients (12.8%) who had an NF‐
pNET ≤2 cm. In particular, patients with an NF‐pNET measuring 1.5 to
2 cm had a two‐fold increased risk of LNM compared with patients who
had an NF‐pNET <1.5 cm (17.9% vs 8.7%). Several previous reports had
similarly suggested a strong relationship between tumor size and risk of
LNM.17,20,33 For example, Kuo et al17 reported an LNM incidence of 36%
among patients with a pNET tumor measuring 16 to 20mm vs 54%
among patients with pNETs measuring and or >20mm. Therefore, small
pNET tumor size does not necessarily preclude the risk of metastasis to
the regional nodal basin.15,17 In turn, patients with small NF‐pNETs
measuring >1.5 cm should undergo formal lymphadenectomy at the time
of resection.
Several limitations should be considered when interpreting data in
the current study. While the multi‐institutional nature of the study
undoubtedly increased the sample size, as well as the “real‐world”
application and generalizability of the data, there likely were some
inconsistencies in patient selection for surgery, surgical techniques, as
well as postoperative surveillance. There were also no patients with
G3 ≤2 cm tumors, which was not surprising as these patients are
generally not considered for surgical management and should be
treated with systemic therapy.34 In addition, only patients undergoing
curative‐intent resection for pNETs were included in the analytic
cohort. As such, there was no observation/surveillance group that
consisted of patients with small NF‐pNETs to serve as a comparator to
assess the “true” benefit of surgery. The purpose of the study, however,
was to determine the incidence and risk factors of LNM, as well as
outcomes of patients with small NF‐pNETs who underwent surgery.
In conclusion, assessing a large, US multi‐institutional national
cohort of patients with pNETs, roughly two out of every five patients
who underwent curative‐intent resection had a tumor ≤2 cm. Among
patients undergoing surgical resection for small NF‐pNETs, more
than 1 in 10 patients had LNM. Patients with a tumor of 1.5‐2 cm had
a two‐fold increase in the incidence of LNM vs patients with tumor
<1.5 cm, as well as a higher risk of advanced tumor grade and higher
Ki‐67 levels. The presence of LNM was independently associated
with a worse long‐term RFS. While some previous studies have
suggested that pNETs <2 cm are simply safe to follow,17,20,21 data
from the current study strongly suggest that surgical resection with
lymphadenectomy should be considered for patients with NF‐pNETs
≥1.5‐2.0 cm.
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